Prognostic and clinicopathological differences of DcR3 in gastrointestinal cancer: Evidence from meta-analysis

International Journal of Clinical and Experimental Medicine

Volumn 7, Issue 9, 2014, Pages 3096-3105

  Tong, Jing ^a   Ao, Ran ^a   Wang, Ying ^a   Chang, Bing ^a   Wang, Bing Yuan ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

DcR3; Gastrointestinal cancer; Metastasis; Prognostic

Indexed keywords

DECOY RECEPTOR 3;

ARTICLE; CANCER INFILTRATION; CANCER PROGNOSIS; CANCER STAGING; DATA EXTRACTION; DIGESTIVE SYSTEM CANCER; GENE OVEREXPRESSION; HUMAN; LYMPH NODE METASTASIS; MEDICAL LITERATURE; META ANALYSIS; PATHOLOGY; PROTEIN EXPRESSION; PUBLICATION; QUALITY CONTROL; TUMOR DIFFERENTIATION;

EID: 84907856070     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Chen J, Zhang L and Kim S. Quantification and detection of DcR3, a decoy receptor in TNFR family. J Immunol Methods 2004; 285: 63-70.
2. Chen L, Tian X, Li W, Agarwal A and Zhuang G. Expressions of Fas/DcR3 and RGD-FasL mediated apoptosis in pituitary adenomas. Neurol India 2009; 57: 28-30.
3. Mueller AM, Pedre X, Killian S, David M and Steinbrecher A. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009; 209: 57-64.
4. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003; 105: 724-732.
5. Yang M, Chen G, Dang Y and Luo D. Significance of decoy receptor 3 in sera of hepatocellular carcinoma patients. Ups J Med Sci 2010; 115: 232-237.
6. Li GH. The expression and significance of DcR3 and Survivin in colorectal carcinoma. Thesis, Guangdong Medical College, China, 2008.
7. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25: 603-605.
8. Liang QL, Wang BR and Li GH. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters. J Zhejiang Univ Sci B 2009; 10: 675-682.
9. Ao R, Du YQ, Wang Y, Chen YS and Wang BY. MMP-2 and DcR3 expression in esophageal cancer tissue and correlation with patient survival. Int J Clin Exp Med 2013; 6: 700-705.
10. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant’Agnese PA, Lei JY. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 2005; 124: 282-287.
11. Xiong G, Guo H, Ge X, Xu X, Yang X, Yang K, Jiang Y, Bai Y. Decoy receptor 3 expression in esophageal squamous cell carcinoma: correlation with tumour invasion and metastasis. Biomarkers 2011; 16: 155-160.
12. Takahama Y, Yamada Y, Emoto K, Fujimoto H, Takayama T, Ueno M, Uchida H, Hirao S, Mizuno T, Nakajima Y. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas. Gastric Cancer 2002; 5: 61-68.
13. Chen G and Luo D. Over-expression of decoy receptor 3 in gastric precancerous lesions and carcinoma. Ups J Med Sci 2008; 113: 297-304.
14. Yang D, Fan X, Yin P, Wen Q, Yan F, Yuan S, Liu B, Zhuang G, Liu Z. Significance of decoy receptor 3 (Dcr3) and external-signal regulated kinase 1/2 (Erk1/2) in gastric cancer. BMC Immunol 2012; 13: 28.
15. Liu Z., Chen SH, Chen YJ, Xu W., Xie LX, Shen JH, Ni YP. Expression of TR6 and survivin gene in the tissue of cardiac caner and its clinical significance. Journal of Chinese Physician 2008; 10: 1336-1338.
16. Zhu QS, Chen P, Zhao W. The Expression of DcR3 and HER-2/neu in 60 Cases with Colorectal Cancer and its Clinical Significance. Journal of Chinese Oncology 2011; 17: 610-613.
17. Yang SG. Expression of Dcr3, EGFR and Ki67 In colorectal carcinoma and its clinical significance. Thesis, Fujian Medical University, China, 2008.
18. Cai YL. Expression DcR3 of in carcinoma of gallbladder. Thesis, Tianjin Medical University, China, 2010.
19. Chen ZM, Ren SL, Zhang L. Expression of decay receptor 3 and the effect on angiogenesis in hepatic cell carcinoma. China Journal of Modern Medicine 2009; 19: 1790-1796.
20. Shen HW, Wu YL and Peng SY. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof. Zhonghua Yi Xue Za Zhi 2003; 83: 744-747.
21. Chen G. Expression of DcR3 and its function on the Growth, Migrating and apoptosis in Hepatocel1u1ar Carcinoma. PhD thesis, Guangxi Medical University, China, 2007.
22. Yu JX. The study on the relationship between DcR3 expression and lymph node metastasis, VEGF-C, VEGF-D expression in gastric cancer. PhD thesis, Zhejiang University School of Medicine, China, 2005.
23. Zhang JS. The Level of DcR3 gene in the colorectal carcinoma and the effects on the immunologic balance. Thesis, Hebei Medical University, China, 2009.
24. Cui M, Guo YZ, Hu XY, Zhou ZW, Xu W. Expression and clinical significance of decoy receptor 3 and Caveolin-1 in hepatocellular carcinoma. The Journal of Practical Medicine 2012; 28: 3902-3904.
25. Liu J. Clinical significance of DcR3, bcl-2 and P53 protein expressinon in esophageal carcinoma. Thesis, Soochow University, China, 2011.
26. Zhang KJ, Wu ZY, Zhang SY, Shen JH. Expression and significance of Survivin and DcR3 in gastric carcinoma. Guangdong Medical Journal 2010; 31: 1157-1158.
27. Yue QF, Xiang M, Li FM, Liu H, Yue FT, Liu J., Wang WQ, Ji CH. Study on the expression level of DcR3 and MMP-2 in esophageal carcinoma and its impact on survival of the patients. China Oncology 2010; 20: 745-750.
28. Li P, Huang CM, Zhang XF. Expression of DcR3 and Ki-67 in human gastric carcinoma and its clinical significance. J Fujian Med Univ 2004; 38: 39-42.
29. Zhao Y, Deng X, Ma Y, Wang P. Expression and clinical significance of PTEN Fas/FasL and DCR3 in gastric cancer. Modern Oncology 2009; 17: 1124-1129.
30. Guo L, Gao X, Lu RQ. The expression and clinical significance of DcR3 and Smad4 in gastric cancer. Laboratory Medicine 2009; 24: 823-827.
31. Zhou J, Song SD, Li DC, Zhu DM and Zheng SY. Clinical significance of expression and amplification of the DcR3 gene in pancreatic carcinomas. Asian Pac J Cancer Prev 2012; 13: 719-724.
32. Shen HW, Gao SL, Wu YL and Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005; 11: 5926-5930.
33. Liu Z., Ni YP, Huang QG, Xie LX, Xu W., Zhong XY. Relation of expression of DcR3 and livin and prognosis in colorectal carcinoma. Guangdong Medical Journal 2013; 34: 1055-1057.
34. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, Godowski PJ, Wood WI, Gurney AL, Hillan KJ, Cohen RL, Goddard AD, Botstein D, Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699-703.
35. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R and Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274: 13733-13736.
36. Migone TS, Zhang J, Luo X, Zhuang L, Chen C, Hu B, Hong JS, Perry JW, Chen SF, Zhou JX, Cho YH, Ullrich S, Kanakaraj P, Carrell J, Boyd E, Olsen HS, Hu G, Pukac L, Liu D, Ni J, Kim S, Gentz R, Feng P, Moore PA, Ruben SM, Wei P. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479-492.
37. Chen G, Luo D., Wang Y, Liao ZL and Zhang MY. Relationship between expression of decoy receptor 3 and apoptosis in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 2007; 36: 113-117.
38. Chen G and Luo D. Expression of decoy receptor 3 in liver tissue microarrays. Natl Med J India 2008; 21: 275-278.
39. Arakawa Y, Tachibana O, Hasegawa M, Miyamori T, Yamashita J and Hayashi Y. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma. Acta Neuropathol 2005; 109: 294-298.
40. Connor JP and Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol 2008; 111: 330-335.
41. Anderson GL, McIntosh M, Wu L, Barnett M, Goodman G, Thorpe JD, Bergan L, Thornquist MD, Scholler N, Kim N, O’Briant K, Drescher C, Urban N. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. J Natl Cancer Inst 2010; 102: 26-38.
42. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, Ren WH. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012; 130: 2685-2692.